Welcome to our dedicated page for MetaVia news (Ticker: MTVA), a resource for investors and traders seeking the latest updates and insights on MetaVia stock.
MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on cardiometabolic diseases, and its news flow centers on the development of two key product candidates: DA-1726 for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and vanoglipel (DA-1241) for MASH and type 2 diabetes. Company announcements frequently highlight clinical trial progress, new data readouts, and regulatory or listing updates that are relevant to investors and healthcare professionals following obesity and liver disease therapeutics.
News about DA-1726 includes Phase 1 multiple ascending dose results in obese but otherwise healthy adults, pharmacokinetic data supporting once-weekly subcutaneous dosing, and extended 8-week dosing cohorts at 48 mg. MetaVia has reported statistically significant weight loss, reductions in waist circumference, improvements in fasted glucose, and reductions in liver stiffness as measured by vibration-controlled transient elastography (VCTE), along with a favorable safety and tolerability profile. The company also releases updates on scientific presentations at meetings such as ObesityWeek, where DA-1726 data are shared with the medical community.
For vanoglipel (DA-1241), MetaVia’s news coverage includes Phase 2a trial results in presumed MASH patients, showing clinically meaningful reductions in glycated hemoglobin (HbA1c), improvements in liver inflammation and fibrosis markers, better liver steatosis and stiffness measures, and favorable shifts in plasma lipidomic profiles. The company announces poster presentations at major conferences such as the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, where detailed hepatic and metabolic data are presented.
In addition to clinical data, MetaVia issues news on corporate and capital market developments, including its 1-for-11 reverse stock split and communications regarding compliance with Nasdaq’s minimum bid price requirement. Readers of the MTVA news page can expect updates on trial milestones, conference presentations, research collaborations, and listing status, providing a consolidated view of MetaVia’s progress in cardiometabolic and liver disease drug development.
MetaVia (Nasdaq: MTVA) announced on December 22, 2025 that it received Nasdaq notice dated December 19, 2025 confirming the company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).
The notice states MetaVia also satisfies all other applicable Nasdaq listing criteria and that the related listing matter has been closed on the Nasdaq Capital Market.
MetaVia (Nasdaq: MTVA) announced a 1-for-11 reverse stock split of its common stock, effective 5:00 p.m. ET on December 4, 2025, with trading on a split-adjusted basis beginning December 5, 2025.
The reverse split was authorized by stockholders June 30, 2025, and approved by the board at a 1-for-11 ratio to help the company comply with Nasdaq continued listing requirements. Outstanding shares will fall from approximately 25.4 million to 2.3 million, while the number of authorized shares remains 100 million. Conversion and exercise prices for restricted stock units, options and warrants will increase proportionally.
Any fractional shares will be rounded down and paid in cash based on the closing Nasdaq price on the last trading day before the split. The stock will continue to trade under the symbol MTVA and a new CUSIP will be 64132R503.
MetaVia (Nasdaq: MTVA) presented positive Phase 2a data for oral GPR119 agonist vanoglipel (DA-1241) in presumed MASH at AASLD 2025.
In a 16-week randomized, placebo-controlled trial of 109 patients, vanoglipel produced mean HbA1c reductions of –0.54%p (monotherapy) and –0.66%p (100 mg + DPP4i) at Week 16; early HbA1c drops were seen by Week 4. Treatment improved liver inflammation, steatosis (CAP), and liver stiffness (VCTE), lowered biomarkers of cell death, inflammation and fibrosis (CK18F/M30, hs-CRP, CCL2, TIMP1), and reduced pathogenic plasma lipids (glycerolipids DG36:4, TG52:4; glycerophospholipids PE38:4, PE38:5). Vanoglipel was well tolerated with no treatment-emergent discontinuations attributed to drug.
MetaVia (Nasdaq: MTVA) reported Q3 2025 results and a corporate update on Nov 6, 2025. Key clinical highlights include dosing the first patient in an 8-week, 48 mg MAD cohort of DA-1726 with top-line data expected by year-end 2025, Phase 1 results showing up to 6.3% mean body-weight reduction, up to 3.9-inch waist reduction, linear dose-proportional PK and an ~80-hour half-life supporting once-weekly dosing. Vanoglipel (DA-1241) Phase 2a showed reductions in liver fat, inflammation and fibrosis; full data to be presented at AASLD 2025. Financially, cash was $14.3M at Sept 30, 2025, expected to fund operations into 2026.
MetaVia (Nasdaq: MTVA) will present new Phase 1 and preclinical data on DA-1726 at ObesityWeek® 2025 (Nov 4-7, 2025). Phase 1 results after four weeks showed favorable safety, tolerability, linear dose-proportional PK with an approximate 80-hour half-life, and clinically meaningful weight loss without titration.
At the 32 mg dose participants had up to 6.3% weight reduction (mean 4.3% at Day 26) and waist decreases up to 3.9 inches. No serious adverse events or discontinuations were reported. Preclinical DIO mouse data showed comparable weight loss to pemvidutide and superior lipid reductions versus pemvidutide and tirzepatide, driven partly by increased energy expenditure.
MetaVia (Nasdaq: MTVA) announced an accepted poster presentation on Vanoglipel (DA-1241), a GPR119 agonist, at the AASLD Liver Meeting 2025 in Washington, D.C., November 7–11, 2025.
The poster reports results from a 16-week randomized placebo-controlled trial in presumed MASH patients assessing hepatoprotective effects through improvements in inflammation and liver metabolism. Presenting author is Rohit Loomba, M.D., MHSc.
Poster details: Poster 4012, Session: Monday Poster Presenters Hall Hour; Date: Monday, November 10, 2025; Time: 1:00–2:00 pm ET; Location: Convention Center Hall DE, Level 2. A copy will be posted in the Posters section of MetaVia's website after the presentation.
MetaVia (Nasdaq: MTVA) announced two poster presentations on DA-1726, a dual oxyntomodulin analogue acting on GLP1R and GCGR, accepted for ObesityWeek® 2025 in Atlanta, November 4-7, 2025.
Both posters will be presented in Exhibit Hall A1 on Tuesday, November 4, 2025, 7:30-8:30 pm ET. Poster P-209 covers safety, tolerability, and pharmacokinetics from a Phase 1 study (presenting author Chris Fang, M.D.). Poster P-154 discusses DA-1726 as a therapy for obesity (presenting author Tae-Hyoung Kim, M.S.). Posters will be posted on the company website after presentation.
MetaVia (Nasdaq: MTVA) announced that President and CEO Hyung Heon Kim will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025.
MetaVia also said CFO Marshall H. Woodworth will join one-on-one meetings with investors during the conference. Institutional investors registered for the event can request meetings via www.hcwevents.com. Investors wishing to meet outside the conference may contact Michael Miller at mmiller@rxir.com.
MetaVia (Nasdaq: MTVA), a clinical-stage biotech company specializing in cardiometabolic diseases, has announced its participation in several upcoming investor and industry conferences from September to October 2025.
CEO Hyung Heon Kim will attend the Wells Fargo Healthcare Conference (Sept 3-5), participate in a fireside chat at the H.C. Wainwright Global Investment Conference (Sept 8-10), present at the Obesity Science & Innovation Congress (Sept 16-17), and attend the Fierce Biotech Week (Oct 7-9). At the Obesity Science conference, Kim will showcase DA-1726, the company's dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity treatment.
MetaVia (NASDAQ: MTVA) reported Q2 2025 financial results and provided updates on its cardiometabolic drug pipeline. The company dosed the first patient in an extended 8-week 48mg MAD cohort for DA-1726, their obesity treatment candidate. Previous 32mg dose cohort showed promising results with 4.3% average weight loss (max 6.3%) by Day 26.
The company also announced an AI-driven collaboration with Syntekabio to explore additional indications for DA-1241, their MASH treatment candidate. New preclinical data showed synergistic benefits when combining DA-1241 with Efruxifermin in reducing liver fat, inflammation, and fibrosis.
Financial highlights include $17.6 million cash position expected to fund operations into 2026, reduced R&D expenses to $2.3 million (down from $8.1 million YoY), and a net loss of $4.0 million ($0.26 per share) for Q2 2025.